Eskild Petersen1. 1. Department of Gastrointestinal and Parasitic Diseases, World Health Organization, National Malaria Diagnostic Reference Center, Statens Serum Institut, Copenhagen, Denmark.
Abstract
BACKGROUND: Data on the long-term safety of atovaquone/proguanil in nonimmune travelers are limited. METHODS: An open-label study, involving 300 Danish soldiers stationed in Eritrea for 6 months was initiated. The subjects self-reported their symptoms on a post-travel questionnaire. The study compared the symptoms of compliers and noncompliers. RESULTS: No serious adverse events occurred. Diarrhea, stomach pain, headache, cough, and loss of appetite were the most common symptoms reported. No case of Plasmodium falciparum malaria occurred. CONCLUSIONS: Atovaquone/proguanil was safe and well tolerated in this group of long-term nonimmune travelers.
BACKGROUND: Data on the long-term safety of atovaquone/proguanil in nonimmune travelers are limited. METHODS: An open-label study, involving 300 Danish soldiers stationed in Eritrea for 6 months was initiated. The subjects self-reported their symptoms on a post-travel questionnaire. The study compared the symptoms of compliers and noncompliers. RESULTS: No serious adverse events occurred. Diarrhea, stomach pain, headache, cough, and loss of appetite were the most common symptoms reported. No case of Plasmodium falciparum malaria occurred. CONCLUSIONS:Atovaquone/proguanil was safe and well tolerated in this group of long-term nonimmune travelers.
Authors: Christian T Happi; Grace O Gbotosho; Onikepe A Folarin; Danny Milner; Ousmane Sarr; Akintunde Sowunmi; Dennis E Kyle; Wilbur K Milhous; Dyann F Wirth; Ayoade M J Oduola Journal: Malar J Date: 2006-10-04 Impact factor: 2.979